Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000668364 | SCV000792949 | uncertain significance | Alstrom syndrome | 2017-08-02 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000668364 | SCV001507195 | uncertain significance | Alstrom syndrome | 2022-06-27 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid with glycine at codon 3663 of the ALMS1 protein (p.Glu3663Gly). The glutamic acid residue is highly conserved and there is a moderate physicochemical difference between glutamic acid and glycine. This variant is present in population databases (rs377418428, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with ALMS1-related conditions. ClinVar contains an entry for this variant (Variation ID: 553003). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV003128687 | SCV003805479 | uncertain significance | not provided | 2023-02-09 | criteria provided, single submitter | clinical testing | Not observed at a significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV003303095 | SCV003999430 | uncertain significance | Cardiovascular phenotype | 2023-03-28 | criteria provided, single submitter | clinical testing | The p.E3663G variant (also known as c.10988A>G), located in coding exon 16 of the ALMS1 gene, results from an A to G substitution at nucleotide position 10988. The glutamic acid at codon 3663 is replaced by glycine, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000668364 | SCV002078993 | uncertain significance | Alstrom syndrome | 2019-10-28 | no assertion criteria provided | clinical testing |